Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
KAREX (5247)
MBOW Public Output v3.4-p1
Current Price: 0.585
中文输出
核心结论
当前结构属于“下跌趋势中的阶段性反弹”,不是趋势反转。短线(30m / 4H / 日线)已经形成连续修复共振,但周线与月线仍处在明确下降结构内,且未突破关键压制区。结论:短线可交易,中线偏弱,长线仍空头主导。
结构分析
月线维持长期下降趋势,价格仍在云层下方,结构没有反转基础,只是低位反弹。 周线出现技术性反弹,MACD低位回升,Fisher从深弱区反弹,但整体仍在下降轨道内。 日线结构已经转强,价格重新站上短期均衡区,MACD上行,Fisher进入强区,是当前反弹主导周期。 4H形成连续抬高结构,动能清晰,是当前主升推动来源。 30m已进入震荡偏高区,存在短线动能衰减风险。
多时间框架共振
30m + 4H + 日线同步向上,这是反弹成立的核心。 但周线与月线没有共振,意味着上涨空间天然受限。 属于“逆势反弹”,不是“顺势趋势”。
关键价格位
第一支撑:0.560–0.570(短线结构关键位) 第二支撑:0.520–0.535(反弹失败确认区) 第一压力:0.600–0.620(短线突破区) 关键压力:0.650–0.700(周线结构压制区)
Path A/B/C 场景推演
Path A(40%) 维持0.560上方震荡,突破0.620后延续反弹,目标0.650–0.700区间。
Path B(40%) 在0.560–0.600之间震荡整理,消化动能,形成横盘结构。
Path C(20%) 跌破0.560,反弹失败,回落至0.520甚至更低,重新进入弱势结构。
最终判断
Current Structure State: 短线反弹 / 中线偏弱 / 长线下降
MBOW Long-Term Rating: C
MBOW Short-Term Rating: B
MBOW Composite Rating: B-
Recommendation Status: 观察
Recommendation Grade: B-
结论一句话: 这是“逆势反弹股”,不是趋势股。能做短线,但不适合当作中长线主升逻辑。
English Short Output (with path)
KAREX (5247) is in a counter-trend rebound within a larger downtrend. Short-term structure (30m, 4H, Daily) is bullish, but Weekly and Monthly remain bearish. Key support is 0.560–0.570, with resistance at 0.600–0.620 and major barrier at 0.650–0.700. Path A (40%) continuation above 0.560 toward 0.620 and possibly 0.650–0.700. Path B (40%) consolidation between 0.560–0.600. Path C (20%) breakdown below 0.560 leading to renewed weakness.
Disclaimer
本分析仅基于图表结构与指标状态,不构成任何投资建议。市场走势会随资金、消息与波动变化,路径概率会动态调整。
This analysis is based on chart structure and indicators only. It is not financial advice. Market conditions can change rapidly, and all probabilities are subject to change with new price action.
Karex is something like selling kacang putih by the roadside.
It is not impressive at all over years of listing status. The management team may be too tired testing the new condoms every night and losing their focus in the office.
now, cimb gives karex a reasonably good forward rating which karex can never dream of since it's Ipo listing which only sparkles for a little while for director goh siang to escape.